JP2017529074A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529074A5
JP2017529074A5 JP2017513004A JP2017513004A JP2017529074A5 JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5 JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5
Authority
JP
Japan
Prior art keywords
mrna
cancer
ercc1 isoform
therapeutic agent
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529074A (ja
JP7057668B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071170 external-priority patent/WO2016042009A1/en
Publication of JP2017529074A publication Critical patent/JP2017529074A/ja
Publication of JP2017529074A5 publication Critical patent/JP2017529074A5/ja
Application granted granted Critical
Publication of JP7057668B2 publication Critical patent/JP7057668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513004A 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Active JP7057668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185247 2014-09-18
EP14185247.5 2014-09-18
PCT/EP2015/071170 WO2016042009A1 (en) 2014-09-18 2015-09-16 Mrna and/or protein of ercc1 isoform 3 for use in diagnosing a resistance against a therapeutic agent and method for diagnosing a resistance against a therapeutic agent using said mrna and/or protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168483A Division JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Publications (3)

Publication Number Publication Date
JP2017529074A JP2017529074A (ja) 2017-10-05
JP2017529074A5 true JP2017529074A5 (enExample) 2018-08-23
JP7057668B2 JP7057668B2 (ja) 2022-04-20

Family

ID=51542262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513004A Active JP7057668B2 (ja) 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Country Status (4)

Country Link
US (1) US20170233826A1 (enExample)
EP (1) EP3194616B1 (enExample)
JP (2) JP7057668B2 (enExample)
WO (1) WO2016042009A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3642351A1 (en) * 2017-06-20 2020-04-29 Nantomics, LLC USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC
US20230383363A1 (en) * 2020-11-04 2023-11-30 GC Genome Corporation Method for determining sensitivity to parp inhibitor or dna damaging agent using non-functional transcriptome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466896A1 (en) * 2001-09-06 2003-03-20 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
US9702875B2 (en) * 2006-03-14 2017-07-11 Institute Gustave-Roussy Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
JP5025724B2 (ja) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション 循環腫瘍性細胞からのタンパク質の検出
EP2233589A1 (en) * 2009-03-19 2010-09-29 Institut Gustave Roussy MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
EP2473619A4 (en) * 2009-09-03 2013-03-27 Scripps Research Inst METHOD FOR CATEGORIZING CIRCULATING TUMOR CELLS
WO2012051390A1 (en) * 2010-10-14 2012-04-19 Veridex, Llc Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents

Similar Documents

Publication Publication Date Title
Zhao et al. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application
Kang et al. Dual‐isolation and profiling of circulating tumor cells and cancer exosomes from blood samples with melanoma using immunoaffinity‐based microfluidic interfaces
Yang et al. Elevated CD163+/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer
Stovgaard et al. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
Ahlin et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
M Braden et al. Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence
Anantharaman et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
Chundong et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis
Munzone et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
EP3488238B1 (en) Combination test for colorectal cancer
Taliano et al. Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis
Rim et al. Quantitative analysis of exosomes from murine lung cancer cells by flow cytometry
JP2016536568A5 (enExample)
Minamoto et al. Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes
Pontikakis et al. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Shi et al. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma
Xu et al. Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer
Gheni et al. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings
Franceschini et al. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology
Koutras et al. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
Malinowsky et al. Targeted therapies in cancer-challenges and chances offered by newly developed techniques for protein analysis in clinical tissues
WO2018096072A1 (en) Biomarkers for the prognosis and diagnosis of cancer
Jagdis et al. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment
Meng et al. Expression of human epidermal growth factor receptor-2 in resected rectal cancer